ABOS•benzinga•
Acumen Pharmaceuticals Announced That The Journal Of Prevention Of Alzheimer's Disease Published The Results Of The Phase 1 INTERCEPT-AD Trial Demonstrating That Sabirnetug (ACU 193) Was Generally Well-tolerated With Dose- And Exposure-dependent Target En
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 9, 2025 by benzinga